Table 3.
All estimates of time to event analysis
| HR | 95% CI | p-val | |
|---|---|---|---|
| Colchicine + Rosuvastatin | |||
| Crude | 0.839 | (0.480 - 1.466) | 0.537 |
| Frailty | 0.776 | (0.443 - 1.360) | 0.376 |
| Frailty-Adjusted | 0.719 | (0.408 - 1.265) | 0.252 |
| FTC/TDF + Colchicine + Rosuvastatin | |||
| Crude | 0.598 | (0.328 - 1.093) | 0.095 |
| Frailty | 0.527 | (0.288 - 0.964) | 0.038 |
| Frailty-Adjusted | 0.483 | (0.263 - 0.887) | 0.019 |
| FTC/TDF | |||
| Crude | 0.786 | (0.449 - 1.373) | 0.397 |
| Frailty | 0.685 | (0.390 - 1.201) | 0.187 |
| Frailty-Adjusted | 0.605 | (0.343 - 1.065) | 0.081 |
HR: Hazard Ratio. FTC/TDF: Emtricitabine/Tenofovir disoproxil fumarate. Crude: HR estimated from Cox regression models. Frailty: HR estimated from shared-frailty (ie, hospital random-effects) Cox models. Frailty-Adjusted: HR estimated from shared-frailty (i.e., hospital random-effects) Cox models adjusted by age, sex, and pneumonia severity. The global tests of proportional-hazards assumption on the basis of Schoenfeld residuals for each model are: Crude model chi2=5.34 (p=0.15); Frailty model chi2=5.76 (p=0.12); Frailty-Adjusted model chi2=9.74 (p=0.14).